CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Phase 1 Study of No-Carrier Added ¹⁷⁷Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea

Hyun Gee Ryoo, Minseok Suh, Keon Wook Kang, Dae-Won Lee, Sae-Won Han, Gi Jeong Cheon

Cancer Research and Treatment. 2023;55(1):334-343. Published online 2022 April 22 DOI: https://doi.org/10.4143/crt.2021.1022

Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea

Hyun Gee Ryoo, Minseok Suh, Keon Wook Kang, Dae-Won Lee, Sae-Won Han, Gi Jeong Cheon

Cancer Research and Treatment. 2023;55(1):334-343

Link1

Link2 Link3

Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with¹⁷⁷Lu-DOTATATE

Santosh K. Gupta, Suhas Singla, Chandrasekhar Bal

Cancer Biotherapy and Radiopharmaceuticals. 2012;27(9):593-599

Link1 Link2

<sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors

Ulrika Jahn, Ezgi Ilan, Mattias Sandström, Ulrike Garske-Román, Mark Lubberink, Anders Sundin

Neuroendocrinology. 2019;110(7-8):662-670

Link1 Link2

Combined use of ¹⁷⁷ Lu‐DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well‐differentiated neuroendocrine tumors: A preclinical study

Jingjing Fu, Fan Qiu, Cati Raluca Stolniceanu, Fei Yu, Shiming Zang, Yili Xiang, Yue Huang, Milovan Matovic, Cipriana Stefanescu, Qiyun Tang, Feng Wang

Journal of Neuroendocrinology. 2022;34(4):

Link1 Link2 Link3

Safety and response after peptide receptor radionuclide therapy with ¹⁷⁷ Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial

Atsushi Kudo, Ukihide Tateishi, Ryoichi Yoshimura, Junichi Tsuchiya, Kota Yokoyama, Shoko Takano, Noritoshi Kobayashi, Daisuke Utsunomiya, Masaharu Hata, Yasushi Ichikawa, Minoru Tanabe, Makoto Hosono, Seigo Kinuya

Journal of Hepato-Biliary-Pancreatic Sciences. 2021;29(4):487-499

Link1 Link2 Link3

Treatment of neuroendocrine tumours with ¹⁷⁷ Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management

Shaunak Navalkissoor, Christos Toumpanakis, Martyn Caplin, Gopinath Gnanasegaran

Journal of Neuroendocrinology. 2022;34(4):

Link1 Link2 Link3

¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models

Samina Roohi, Shakera Khatoon Rizvi, Syed Ali Raza Naqvi

Dose-Response. 2021;19(1):155932582199014

Link1 Link2 Link3

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with¹⁷⁷Lu-DOTATATE and⁹⁰Y-DOTATOC

Maribel L. Sierra, Alberto Agazzi, Lisa Bodei, Monica Pacifici, Demetrio Aricò, Concetta De Cicco, Jessica Quarna, Maddalena Sansovini, Michele De Simone, Giovanni Paganelli

Cancer Biotherapy and Radiopharmaceuticals. 2009;24(6):659-665

Link1 Link2

Single centre retrospective review of outcome of ¹⁷⁷ Lu‐DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors

Shahad Alsadik, Gopinath Gnanasegaran, Luohai Chen, Ann‐Marie Quigley, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin, Shaunak Navalkissoor

Journal of Neuroendocrinology. 2022;34(11):

Link1 Link2 Link3

Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with⁶⁸Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy

Wolfgang Luboldt, Holger Hartmann, Bärbel Wiedemann, Klaus Zöphel, Hans-Joachim Luboldt

Molecular Imaging. 2010;9(6):7290.2010.00035

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.